Overview
Precision oncology firm reported a net loss of $99.5 mln for 2025
Company received FDA clearance for IND application for PRT12396
Cash runway expected into Q2 2027 with $106 mln in cash and equivalents
Outlook
Prelude anticipates Phase 1 study of PRT12396 to start by Q2 2026
Company plans to file IND for PRT13722 in mid-2026
Prelude expects cash runway to last until Q2 2027
Result Drivers
FDA CLEARANCE - Prelude received FDA clearance for IND application for PRT12396, a mutant-selective JAK2V617F inhibitor, marking a key milestone in their strategic focus
KAT6A PROGRAM - Co is advancing its KAT6A degrader program with plans to file an IND in mid-2026 and initiate Phase 1 study in the second half of 2026
DEGRADER PAYLOADS - Prelude is developing novel degrader payloads for next-generation DACs, expanding potential partnerships and technological reach
Company press release: ID:nGNXsg6rZ
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY EPS | -$1.29 | ||
FY Net Income | -$99.50 mln | ||
FY Income from Operations | -$104.57 mln | ||
FY Operating Expenses | $116.71 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Prelude Therapeutics Inc is $4.00, about 29.4% above its March 9 closing price of $3.09
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)